Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24602576 | 0.92 | CNR2 (0.44) | MIFAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL24258804 | 0.85 | AKR1C4 (0.44) | AKR1C4AKR1C3AKR1C2AKR1C1HSD11B1 | |
| SCHEMBL31292171 | 0.81 | HSD11B1 (0.44) | MIFAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL24259680 | 0.81 | MIF (0.36) | MIFAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6326298 | 0.81 | MIF (0.45) | MIFAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL24258971 | 0.79 | ALDH1A1 (0.43) | HDAC1HTTHDAC2HDAC8L3MBTL1 | |
| SCHEMBL24452417 | 0.79 | HDAC1 (0.43) | HDAC1HDAC2HDAC8TSHRHPGD | |
| SCHEMBL13492977 | 0.75 | L3MBTL1 (0.41) | AKR1C4AKR1C3AKR1C2AKR1C1HSD11B1 | |
| SCHEMBL22352584 | 0.75 | HDAC1 (0.41) | HDAC1HDAC2HDAC8TSHRHPGD | |
| SCHEMBL24258815 | 0.75 | HPGD (0.39) | MIFTSHRHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | MIF 940/4885AKR1C4 502/4885AKR1C3 344/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | MIF 940/4885AKR1C4 502/4885AKR1C3 344/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | MIF 940/4885AKR1C4 502/4885AKR1C3 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.